Hypertension in CKD: Core Curriculum 2019

Research output: Contribution to journalReview article

Elaine Ku, Benjamin J Lee, Jenny Wei, Matthew R Weir

Hypertension and chronic kidney disease (CKD) are closely interlinked pathophysiologic states, such that sustained hypertension can lead to worsening kidney function and progressive decline in kidney function can conversely lead to worsening blood pressure (BP) control. The pathophysiology of hypertension in CKD is complex and is a sequela of multiple factors, including reduced nephron mass, increased sodium retention and extracellular volume expansion, sympathetic nervous system overactivity, activation of hormones including the renin-angiotensin-aldosterone system, and endothelial dysfunction. Currently, the treatment target for patients with CKD is a clinic systolic BP < 130mm Hg. The main approaches to the management of hypertension in CKD include dietary salt restriction, initiation of treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and diuretic therapy. Uncontrolled hypertension can lead to significant cardiovascular morbidity and mortality and accelerate progression to end-stage kidney disease. Although intensive BP control has not been shown in clinical trials to slow the progression of CKD, intensive BP control reduces the risk for adverse cardiovascular outcomes and mortality in the CKD population.

Original languageEnglish (US)
Pages (from-to)120-131
Number of pages12
JournalAmerican journal of kidney diseases : the official journal of the National Kidney Foundation
Volume74
Issue number1
DOIs
StatePublished - Jul 2019

PMID: 30898362

Altmetrics

Cite this

Standard

Hypertension in CKD : Core Curriculum 2019. / Ku, Elaine; Lee, Benjamin J; Wei, Jenny; Weir, Matthew R.

In: American journal of kidney diseases : the official journal of the National Kidney Foundation, Vol. 74, No. 1, 07.2019, p. 120-131.

Research output: Contribution to journalReview article

Harvard

Ku, E, Lee, BJ, Wei, J & Weir, MR 2019, 'Hypertension in CKD: Core Curriculum 2019' American journal of kidney diseases : the official journal of the National Kidney Foundation, vol. 74, no. 1, pp. 120-131. https://doi.org/10.1053/j.ajkd.2018.12.044

APA

Ku, E., Lee, B. J., Wei, J., & Weir, M. R. (2019). Hypertension in CKD: Core Curriculum 2019. American journal of kidney diseases : the official journal of the National Kidney Foundation, 74(1), 120-131. https://doi.org/10.1053/j.ajkd.2018.12.044

Vancouver

Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: Core Curriculum 2019. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2019 Jul;74(1):120-131. https://doi.org/10.1053/j.ajkd.2018.12.044

Author

Ku, Elaine ; Lee, Benjamin J ; Wei, Jenny ; Weir, Matthew R. / Hypertension in CKD : Core Curriculum 2019. In: American journal of kidney diseases : the official journal of the National Kidney Foundation. 2019 ; Vol. 74, No. 1. pp. 120-131.

BibTeX

@article{96416a4c0e8b4031a2fb91c3d9979058,
title = "Hypertension in CKD: Core Curriculum 2019",
abstract = "Hypertension and chronic kidney disease (CKD) are closely interlinked pathophysiologic states, such that sustained hypertension can lead to worsening kidney function and progressive decline in kidney function can conversely lead to worsening blood pressure (BP) control. The pathophysiology of hypertension in CKD is complex and is a sequela of multiple factors, including reduced nephron mass, increased sodium retention and extracellular volume expansion, sympathetic nervous system overactivity, activation of hormones including the renin-angiotensin-aldosterone system, and endothelial dysfunction. Currently, the treatment target for patients with CKD is a clinic systolic BP < 130mm Hg. The main approaches to the management of hypertension in CKD include dietary salt restriction, initiation of treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and diuretic therapy. Uncontrolled hypertension can lead to significant cardiovascular morbidity and mortality and accelerate progression to end-stage kidney disease. Although intensive BP control has not been shown in clinical trials to slow the progression of CKD, intensive BP control reduces the risk for adverse cardiovascular outcomes and mortality in the CKD population.",
keywords = "BP control, Hypertension, ambulatory blood pressure monitoring (ABPM), antihypertensive agents, blood pressure (BP), cardiovascular outcomes, chronic kidney disease (CKD), renin-angiotensin system (RAS), review",
author = "Elaine Ku and Lee, {Benjamin J} and Jenny Wei and Weir, {Matthew R}",
note = "Copyright {\circledC} 2019 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.",
year = "2019",
month = "7",
doi = "10.1053/j.ajkd.2018.12.044",
language = "English (US)",
volume = "74",
pages = "120--131",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Hypertension in CKD

T2 - American Journal of Kidney Diseases

AU - Ku, Elaine

AU - Lee, Benjamin J

AU - Wei, Jenny

AU - Weir, Matthew R

N1 - Copyright © 2019 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

PY - 2019/7

Y1 - 2019/7

N2 - Hypertension and chronic kidney disease (CKD) are closely interlinked pathophysiologic states, such that sustained hypertension can lead to worsening kidney function and progressive decline in kidney function can conversely lead to worsening blood pressure (BP) control. The pathophysiology of hypertension in CKD is complex and is a sequela of multiple factors, including reduced nephron mass, increased sodium retention and extracellular volume expansion, sympathetic nervous system overactivity, activation of hormones including the renin-angiotensin-aldosterone system, and endothelial dysfunction. Currently, the treatment target for patients with CKD is a clinic systolic BP < 130mm Hg. The main approaches to the management of hypertension in CKD include dietary salt restriction, initiation of treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and diuretic therapy. Uncontrolled hypertension can lead to significant cardiovascular morbidity and mortality and accelerate progression to end-stage kidney disease. Although intensive BP control has not been shown in clinical trials to slow the progression of CKD, intensive BP control reduces the risk for adverse cardiovascular outcomes and mortality in the CKD population.

AB - Hypertension and chronic kidney disease (CKD) are closely interlinked pathophysiologic states, such that sustained hypertension can lead to worsening kidney function and progressive decline in kidney function can conversely lead to worsening blood pressure (BP) control. The pathophysiology of hypertension in CKD is complex and is a sequela of multiple factors, including reduced nephron mass, increased sodium retention and extracellular volume expansion, sympathetic nervous system overactivity, activation of hormones including the renin-angiotensin-aldosterone system, and endothelial dysfunction. Currently, the treatment target for patients with CKD is a clinic systolic BP < 130mm Hg. The main approaches to the management of hypertension in CKD include dietary salt restriction, initiation of treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and diuretic therapy. Uncontrolled hypertension can lead to significant cardiovascular morbidity and mortality and accelerate progression to end-stage kidney disease. Although intensive BP control has not been shown in clinical trials to slow the progression of CKD, intensive BP control reduces the risk for adverse cardiovascular outcomes and mortality in the CKD population.

KW - BP control

KW - Hypertension

KW - ambulatory blood pressure monitoring (ABPM)

KW - antihypertensive agents

KW - blood pressure (BP)

KW - cardiovascular outcomes

KW - chronic kidney disease (CKD)

KW - renin-angiotensin system (RAS)

KW - review

UR - http://www.scopus.com/inward/record.url?scp=85063011514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063011514&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2018.12.044

DO - 10.1053/j.ajkd.2018.12.044

M3 - Review article

VL - 74

SP - 120

EP - 131

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 1

ER -

ID: 49651045